# Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

> **NCT02292758** · PHASE2 · COMPLETED · sponsor: **Academic and Community Cancer Research United** · enrollment: 36 (actual)

## Conditions studied

- Colorectal Adenocarcinoma
- RAS Wild Type
- Stage IV Colorectal Cancer AJCC v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Cetuximab
- **DRUG:** Irinotecan
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02292758
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-12
- **Primary completion:** 2019-03-20
- **Final completion:** 2019-09-27
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02292758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02292758, "Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02292758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*